001     301546
005     20250904144208.0
024 7 _ |a 10.1158/2643-3230.BCD-24-0328
|2 doi
024 7 _ |a pmid:40402512
|2 pmid
024 7 _ |a 2643-3230
|2 ISSN
024 7 _ |a 2643-3249
|2 ISSN
024 7 _ |a altmetric:177333643
|2 altmetric
037 _ _ |a DKFZ-2025-01067
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Diamond, Benjamin
|0 0000-0002-8638-9365
|b 0
245 _ _ |a Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignancies.
260 _ _ |a Philadelphia, PA
|c 2025
|b American Association for Cancer Research
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756989533_27123
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Sep 3;6(5):450-463 / #EA:A360#LA:A360#
520 _ _ |a Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of indels, and their repair by non-homologous end-joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. Here, we interrogated 580 whole-genome sequence samples (WGS) from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet, ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose-response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode we demonstrate that a single RT-surviving cell may seed distant relapse.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Chahar, Dhanvantri
|0 0000-0002-7623-7018
|b 1
700 1 _ |a Jain, Michael D
|0 0000-0002-7789-1257
|b 2
700 1 _ |a Poos, Alexandra
|0 P:(DE-He78)b06e4e56845c7f91bd749bb7e6ac9d51
|b 3
|e First author
|u dkfz
700 1 _ |a Durante, Michael A
|0 0000-0003-3137-6847
|b 4
700 1 _ |a Ziccheddu, Bachisio
|0 0000-0002-2746-0053
|b 5
700 1 _ |a Kaddoura, Marcella
|0 0000-0002-4529-7405
|b 6
700 1 _ |a Papadimitriou, Marios
|0 0009-0009-1852-3495
|b 7
700 1 _ |a Maclachlan, Kylee H
|0 0000-0001-7873-4854
|b 8
700 1 _ |a Jelinek, Tomas
|0 0000-0002-5467-9253
|b 9
700 1 _ |a Davies, Faith E
|0 0000-0002-3971-2393
|b 10
700 1 _ |a Figura, Nicholas B
|0 0000-0002-6885-3320
|b 11
700 1 _ |a Morgan, Gareth J
|0 0000-0002-4271-6360
|b 12
700 1 _ |a Mai, Elias K
|0 0000-0002-6226-1252
|b 13
700 1 _ |a Weisel, Katja
|0 0000-0001-9422-6614
|b 14
700 1 _ |a Fenk, Roland
|0 0000-0001-7594-6288
|b 15
700 1 _ |a Raab, Marc-Steffen
|0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
|b 16
700 1 _ |a Usmani, Saad
|0 0000-0002-5484-8731
|b 17
700 1 _ |a Landgren, Ola
|0 0000-0001-6485-4839
|b 18
700 1 _ |a Locke, Frederick L
|0 0000-0001-9063-6691
|b 19
700 1 _ |a Goldschmidt, Hartmut
|b 20
700 1 _ |a Schatz, Jonathan Harry
|0 0000-0003-1842-228X
|b 21
700 1 _ |a Weinhold, Niels
|0 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
|b 22
|e Last author
|u dkfz
700 1 _ |a Maura, Francesco
|0 0000-0002-5017-1620
|b 23
773 _ _ |a 10.1158/2643-3230.BCD-24-0328
|0 PERI:(DE-600)3028898-8
|n 5
|p 450-463
|t Blood cancer discovery
|v 6
|y 2025
|x 2643-3230
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301546
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)b06e4e56845c7f91bd749bb7e6ac9d51
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD CANCER DISCOV : 2022
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b BLOOD CANCER DISCOV : 2022
|d 2024-12-06
920 2 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
920 1 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
920 0 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A360-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21